Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Coprevalence of Amyloidosis an...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Coprevalence of Amyloidosis and Aortic Stenosis: When to Screen and Who to Treat?

Coprevalence of Amyloidosis and Aortic Stenosis: When to Screen and Who to Treat?

Bibliographic Details
Main Author: Brett W. Sperry
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
Editorials
cardiomyopathy
polyneuropathy
tafamidis
TAVR
vutrisiran
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.124.038279
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.124.038279

Similar Items

  • Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort study
    by: Taha N. Qarni, et al.
    Published: (2024-05-01)
  • Assessing the effectiveness and safety of Patisiran and Vutrisiran in ATTRv amyloidosis with polyneuropathy: a systematic review
    by: Mohammad Amin Karimi, et al.
    Published: (2024-09-01)
  • Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Variant Transthyretin Amyloid Cardiomyopathy
    by: Nicholas Streicher, et al.
    Published: (2024-03-01)
  • Paradigm Shift in the Management of Aortic Stenosis
    by: Santiago Garcia, et al.
    Published: (2024-09-01)
  • Evaluation of Mortality During Long-Term Treatment with Tafamidis for Transthyretin Amyloidosis with Polyneuropathy: Clinical Trial Results up to 8.5 Years
    by: Giampaolo Merlini, et al.
    Published: (2020-02-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs